Aurobindo, Hetero, and Vivimed Class Action Settlements in South Dakota

All Aurobindo, Hetero, and Vivimed class action lawsuits and settlements available to South Dakota residents.

South Dakota residents have 1 active class action settlements involving Aurobindo, Hetero, and Vivimed that they can file claims for right now. Open settlements include $15.2M Valsartan, Losartan and Irbesartan class action settlement.

Class Action Buddy automatically files Aurobindo, Hetero, and Vivimed claims for South Dakota residents in under 60 seconds — no paperwork, no mailing, no proof of purchasey/proof-of-purchase/" style="color:#5D82F2;text-decoration:none;font-weight:500;">proof of purchase needed for most settlements.

About Aurobindo, Hetero, and Vivimed Class Actions in South Dakota

South Dakota residents affected by contaminated blood pressure medications manufactured by Aurobindo, Hetero, and Vivimed have settlement options available through the $15.2 million Valsartan, Losartan and Irbesartan class action settlement. These Indian pharmaceutical companies distributed generic ARB medications containing NDMA and other carcinogenic impurities throughout the United States, including South Dakota pharmacies and healthcare systems. South Dakota's Deceptive Trade Practices Act provides additional consumer protections beyond federal regulations, allowing residents to pursue claims for pharmaceutical fraud and misrepresentation. While these manufacturers don't maintain major operations in South Dakota, their products reached consumers through national pharmacy chains like Hy-Vee, which operates multiple locations across the state. South Dakota follows federal class action procedures under Rule 23, meaning residents can participate in nationwide settlements without filing separate state court actions. The state's four-year statute of limitations for consumer protection claims may provide additional time for filing individual lawsuits beyond class action deadlines. Residents who purchased these contaminated medications between 2012-2018 may be eligible for compensation through the established settlement fund.

Are South Dakota residents eligible for the Aurobindo, Hetero, and Vivimed settlement money?

Yes, South Dakota residents who purchased Valsartan, Losartan, or Irbesartan manufactured by these companies between 2012-2018 can participate in the $15.2 million class action settlement. You don't need to prove injury to receive compensation for purchasing the contaminated medications. Claims must be filed with proper documentation showing purchase of the affected drug products.

Where did South Dakota residents typically purchase these contaminated medications?

South Dakota residents most commonly obtained these ARB medications through Hy-Vee pharmacies, independent pharmacies, and regional healthcare systems like Avera Health and Sanford Health. These medications were also distributed through mail-order pharmacy programs and specialty pharmacy networks serving rural South Dakota communities. The contaminated generics were widely available throughout the state's pharmacy network from 2012-2018.

Can South Dakota residents file individual lawsuits against these manufacturers?

South Dakota residents retain the right to file individual lawsuits under state consumer protection laws even after the class action settlement. The state's Deceptive Trade Practices Act provides a four-year statute of limitations that may extend beyond federal deadlines. However, participating in the class action settlement typically waives rights to pursue separate litigation against the same defendants for the same claims.

Tips for South Dakota Residents Filing Aurobindo, Hetero, and Vivimed Claims

South Dakota residents filing claims should gather pharmacy records from major chains like Hy-Vee and regional health systems that dispensed these medications. Contact your healthcare provider or pharmacy to obtain detailed prescription records showing manufacturer information, as generic medications often switch suppliers. Keep documentation of any medical monitoring or testing performed due to NDMA exposure concerns. Consider consulting with South Dakota attorneys familiar with pharmaceutical litigation, particularly those experienced with the state's Deceptive Trade Practices Act. File claims promptly as settlement deadlines are typically firm, and late submissions may be rejected regardless of merit.

More South Dakota Resources